Carbon Dioxide, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. First approved in 2024.
Drug data last refreshed 3h ago · AI intelligence enriched 5d ago
Carbon Dioxide, USP is an inhaled gas formulation approved as a radiographic contrast agent that functions through X-ray contrast activity to enhance imaging visualization. It is used to improve diagnostic clarity in radiologic procedures by providing enhanced contrast in targeted anatomical regions.
Early-stage commercial product in growth phase with moderate competitive intensity (30% pressure); team expansion likely as market presence establishes.
X-Ray Contrast Activity
Radiographic Contrast Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on Carbon Dioxide, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Carbon Dioxide, USP offers early-stage growth opportunity in a specialized diagnostic imaging market with a newly approved product requiring market establishment. Career trajectory depends on successful commercialization execution and market penetration in the radiographic contrast space.